Summary
Johnson & Johnson (JNJ) filed an 8-K on January 21, 2014, reporting its fourth-quarter and full-year financial results for the period ending December 29, 2013. The filing primarily serves to announce these results, which were detailed in an accompanying press release. Investors should note that this 8-K is an event-driven filing, meaning its primary purpose is to disseminate material financial information in a timely manner. The specific details of the sales and earnings performance are found within the attached exhibits.
Key Highlights
- 1Announcement of Fourth Quarter and Full Year 2013 Sales and Earnings.
- 2Filing includes a press release dated January 21, 2014, detailing the results.
- 3Supplemental financial information, including comparative sales data and condensed consolidated statements of earnings, is provided.
- 4The reporting period concludes on December 29, 2013.
- 5This 8-K filing is focused on the timely dissemination of financial performance information.
- 6Investors can find detailed financial performance metrics within the attached exhibits.
Frequently Asked Questions
The primary purpose of this 8-K filing is to announce and provide Johnson & Johnson's financial results for the fourth quarter and the full year ended December 29, 2013, as detailed in an accompanying press release and supplemental financial data.
The actual sales and earnings figures, along with comparative supplementary sales data and condensed consolidated statements of earnings, are provided in the exhibits attached to this 8-K filing, specifically Exhibit 99.15 (Press Release) and Exhibit 99.20 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings).
These financial results cover the fourth quarter and the full fiscal year of Johnson & Johnson that concluded on December 29, 2013.
This specific 8-K filing focuses on reporting past financial performance for the period ended December 29, 2013. Any forward-looking guidance would typically be found within the press release (Exhibit 99.15) or discussed in management commentary within the exhibits, rather than being a primary disclosure item of the 8-K itself.